160 related articles for article (PubMed ID: 24952367)
1. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer.
Fairfield KM; Murray K; LaChance JA; Wierman HR; Earle CC; Trimble EL; Warren JL
Gynecol Oncol; 2014 Sep; 134(3):473-7. PubMed ID: 24952367
[TBL] [Abstract][Full Text] [Related]
2. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
[TBL] [Abstract][Full Text] [Related]
3. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
[TBL] [Abstract][Full Text] [Related]
4. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer.
Fairfield KM; Murray K; Lucas FL; Wierman HR; Earle CC; Trimble EL; Small L; Warren JL
J Clin Oncol; 2011 Oct; 29(29):3921-6. PubMed ID: 21911719
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
Oaknin A; Roda D; González-Martín A; Chiva L; García-Donas J; de Juan A; Redondo A; Martínez S; García Y; Catot S; Ponce J; Del Campo JM; Cervantes A; Poveda A
Int J Gynecol Cancer; 2011 Aug; 21(6):1048-55. PubMed ID: 21738038
[TBL] [Abstract][Full Text] [Related]
7. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
9. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
Le T; Latifah H; Jolicoeur L; Weberpals J; Faught W; Hopkins L; Fung MF
Gynecol Oncol; 2011 Jun; 121(3):451-4. PubMed ID: 21402403
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
11. Study of efficacy and safety of modified adjuvant intraperitoneal chemotherapy regimen in carcinoma ovary.
Dash P; Goel V; Talwar V; Doval DC; Raina S; Goyal P; Upadhyay A; Patnaik N
Indian J Cancer; 2016; 53(4):607-611. PubMed ID: 28485363
[TBL] [Abstract][Full Text] [Related]
12. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA
Gynecol Oncol; 2011 Jul; 122(1):100-6. PubMed ID: 21496889
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
Jaaback K; Johnson N
Cochrane Database Syst Rev; 2006 Jan; (1):CD005340. PubMed ID: 16437527
[TBL] [Abstract][Full Text] [Related]
15. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients.
Koo YJ; Lim KT
Taiwan J Obstet Gynecol; 2015 Jun; 54(3):275-9. PubMed ID: 26166340
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
18. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
19. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.
Suidan RS; Zhou Q; Iasonos A; O'Cearbhaill RE; Chi DS; Long Roche KC; Tanner EJ; Denesopolis J; Barakat RR; Zivanovic O
Int J Gynecol Cancer; 2015 May; 25(4):599-606. PubMed ID: 25664437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]